Study to evaluate safety, tolerability, pharmacokinetics, and antiviral activity of ritonavir-boosted danoprevir in combination with peginterferon alfa-2a plus ribavirin in treatment-naive patients of Asian origin who have chronic hepatitis c genotype 1 with or without compensated cirrhosis

Trial Profile

Study to evaluate safety, tolerability, pharmacokinetics, and antiviral activity of ritonavir-boosted danoprevir in combination with peginterferon alfa-2a plus ribavirin in treatment-naive patients of Asian origin who have chronic hepatitis c genotype 1 with or without compensated cirrhosis

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Oct 2016

At a glance

  • Drugs Danoprevir/ritonavir (Primary) ; Peginterferon alfa-2a; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 01 Oct 2016 Results assessing sustained virologic response published in the Journal of Gastroenterology and Hepatology.
    • 19 Mar 2016 Results published in the Journal of Gastroenterology and Hepatology
    • 14 Oct 2014 Status changed from active, no longer recruiting to completed, as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top